Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Triaziquone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.32 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | APAF1 | O14727 | 2/20 | 0.38 |
| ▸ | TDP2 | O95551 | 2/20 | 0.38 |
| ▸ | NSD2 | O96028 | 2/20 | 0.38 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GALK1 | P51570 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.36 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triaziquone SCHEMBL6000230 | 0.98 | DNMT1 (0.47) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL7738777 | 0.98 | DNMT1 (0.47) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL7088197 | 0.98 | DNMT1 (0.47) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL8993238 | 0.98 | DNMT1 (0.47) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL5054475 | 0.98 | DNMT1 (0.47) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL19995413 | 0.96 | DNMT1 (0.46) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL4752598 | 0.96 | DNMT1 (0.46) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL8303 | 0.96 | DNMT1 (0.48) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL8482641 | 0.93 | DNMT1 (0.47) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL1538515 | 0.93 | DNMT1 (0.47) | DNMT1MAPTHTTTP53STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149403-A1 | CARBONIC ANHYDRASE ENZYMES FOR REGULATING MAST CELL HEMATOPOIESIS AND TYPE 2 INFLAMMATION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-05-18 | — | — | US | disclosed |
| US-20210115096-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CELIAC DISEASE | IMMUSANT, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-20210052590-A1 | CARBONIC ANHYDRASE ENZYMES FOR REGULATING MAST CELL HEMATOPOIESIS AND TYPE 2 INFLAMMATION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-02-25 | — | — | US | disclosed |
| US-20200289611-A1 | Methods and Compositions for the Inhibition of Quorum Sensing in Bacterial Infections | UNIVERSITY OF NORTH CAROLINA AT GREENSBORO | 2020-09-17 | — | — | US | disclosed |
| US-10758537-B2 | Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type 2 inflammation | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190048047-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CELIAC DISEASE | IMMUSANT, INC. (US) | 2019-02-14 | — | — | US | disclosed |
| US-20180263982-A1 | CARBONIC ANHYDRASE ENZYMES FOR REGULATING MAST CELL HEMATOPOIESIS AND TYPE 2 INFLAMMATION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-09-20 | — | — | US | disclosed |
| EP-3269379-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CELIAC DISEASE | Immusant, Inc. (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2017197303-A1 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF QUORUM SENSING IN BACTERIAL INFECTIONS | UNIVERSITY OF NORTH CAROLINA AT GREENSBORO (US) | 2017-11-16 | — | — | WO | disclosed |
| EP-2977053-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CELIAC DISEASE | IMMUSANT INC (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-0989858-A1 | CD28/CTLA-4 INHIBITING PEPTIDOMIMETICS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHOD OF USING SAME | Applied Research Systems ARS Holding N.V. (AN) | 2000-04-05 | — | — | EP | disclosed |
| WO-1999056753-A1 | HEMATOPOIETIC STIMULATION | POINT THERAPEUTICS, INC. (US) | 1999-11-11 | — | — | WO | disclosed |
| EP-0705258-B1 | AZOLYL-CYCLIC AMINE DERIVATIVES WITH IMMUNOMODULATORY ACTIVITY | KNOLL AG (DE) | 1998-12-30 | — | — | EP | disclosed |
| WO-1998056401-A1 | CD28/CTLA-4 INHIBITING PEPTIDOMIMETICS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHOD OF USING SAME | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 1998-12-17 | — | — | WO | disclosed |
| US-5741800-A | ANTIINFLAMMATORY AGENT, ANTIALLERGENS | KNOLL AKTIENGESELLACHAFT (DE) | 1998-04-21 | — | — | US | disclosed |
| EP-0539584-B1 | REAGENT FOR DIAGNOSING MYCOPLASMA PNEUMONIAE | DOJIN IYAKU KAKO CO LTD (JP) | 1996-11-20 | — | — | EP | disclosed |
| EP-0705258-A1 | AZOLYL-CYCLIC AMINE DERIVATIVES WITH IMMUNOMODULATORY ACTIVITY | Knoll AG (DE) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000507-A1 | AZOLYL-CYCLIC AMINE DERIVATIVES WITH IMMUNOMODULATORY ACTIVITY | KNOLL AG (DE) | 1995-01-05 | — | — | WO | disclosed |
| EP-0539584-A1 | REAGENT FOR DIAGNOSING MYCOPLASMA PNEUMONIAE | DOJIN IYAKU-KAKO CO., LTD. (JP) | 1993-05-05 | — | — | EP | disclosed |
| US-4169137-A | Antigen detecting reagents | BLOCK ENGINEERING, INC. (US) | 1979-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180263982-A1 | CARBONIC ANHYDRASE ENZYMES FOR REGULATING MAST CELL HEMATOPOIESIS AND TYPE 2 INFLAMMATION | CA2, CMA1, CPA3 | GAA 144/4885DNMT1 3433/4885MAPT 4350/4885 |
| US-20200289611-A1 | Methods and Compositions for the Inhibition of Quorum Sensing in Bacterial Infections | PYCARD, LASP1, API5 | GAA 4434/4885DNMT1 2580/4885MAPT 4623/4885 |
| US-10758537-B2 | Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type 2 inflammation | CA2, CMA1, CPA3 | GAA 144/4885DNMT1 3433/4885MAPT 4350/4885 |
| US-20230149403-A1 | CARBONIC ANHYDRASE ENZYMES FOR REGULATING MAST CELL HEMATOPOIESIS AND TYPE 2 INFLAMMATION | CA2, CMA1, CPA3 | GAA 144/4885DNMT1 3433/4885MAPT 4350/4885 |
| US-20210052590-A1 | CARBONIC ANHYDRASE ENZYMES FOR REGULATING MAST CELL HEMATOPOIESIS AND TYPE 2 INFLAMMATION | CA2, CMA1, CPA3 | GAA 144/4885DNMT1 3433/4885MAPT 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.